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Abstract:
Purpose:
Manuka honey is currently used in medical-grade sterile wound treatment products and has been shown to be effective in methicillin-resistant
Staphylococcus aureus (MRSA) killing in vitro and in wound healing in a number of case studies and series. Locally produced honey in Pakistan
and Chile have been proposed to be as effective as Manuka honey in bacterial killing in vitro, presenting potentially more accessible and affordable
alternatives. In this study, we compared the effectiveness of a local Germania honey from Saudi Arabia to Manuka honey MGO 550 for in vitro
killing of MRSA.
Methodology:
Overnight Muller Hinton broth cultures of 50 wound culture isolates of MRSA from 50 patients were incubated with a series of dilutions of
Manuka honey MGO 550 and corresponding Germania honey dilutions for 24 h. Turbidity was assessed to determine whether bacterial growth had
occurred, and no growth was confirmed by a further 24 h sub-culture on blood agar.
Results/Key findings:
Manuka honey MGO 550 was significantly more effective than Germania honey at MRSA killing at 100% v/v, 50% v/v and 25% v/v (p=0.025,
0.000265, and 0.000112 respectively)
Conclusion:
Manuka honey MGO 550 is significantly more effective in killing MRSA in vitro than Germania honey. Germania honey does not appear to be a
promising  locally  produced  alternative  to  Manuka  honey  for  the  development  of  honey-based  wound  dressings.  Further  experiments  could
determine if Germania honey is effective against other bacterial species.
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1. INTRODUCTION
The rise in antimicrobial resistance in bacteria is a major
worldwide public health issue. In the context of bacterial Skin
and  Skin  Structure  Infections  (SSSI),  Skin  and  Soft  Tissue
Infections (SSTI) and wound infections,  methicillin-resistance
Staphylococcus aureus (MRSA) is  of  particular  concern;  the
 emergence  of   Vancomycin-Intermediate  S. aureus  (VISA),
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heterogeneous  VISA,  and  vancomycin-resistant  S.  aureus
(VRSA) strains has further reduced antibiotic options [1 - 4].
Prevalence  of  MRSA  among  SSSIs  and  SSTIs  varies
geographically but is generally high. For example, in a study
on  471,550  SSTI  episodes  in  Northern  California  between
2009 and 2011, S. aureus was the pathogen identified in 81%
of pathogen-positive specimens,  of  which 46% were MRSA,
while  in  a  retrospective  review  of  200  S.  aureus  isolates,  of
which  87.3%  were  SSTIs,  in  the  western  region  of  Saudi
Arabia between 2009 and 2010, MRSA was found in 39.5% of
isolates [1, 5]. Other important antibiotic-resistant bacteria in
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SSTIs  are  Enterobacteriaceae  including  Escherichia,
Klebsiella,  Citrobacter,  Enterobacter  and  Serratia,  such  as
Carbapenem-Resistant  Enterobacteriaceae  (CRE)  and
extended  spectrum  β-lactamase  (ESBL)-expressing  Enter-
obacteriaceae [6 - 8]. Pseudomonas aeruginosa persis-tence in
chronic wounds due to the formation of biofilms and tolerance
of  many  antimicrobial  treatments  is  another  serious  public
health issue [9]. The increasing prevalence of such infections
has  necessitated  attempts  to  identify  alternative  antibiotic
treatments  and  has  also  raised  interest  in  non-antibiotic
therapies.
Honey  is  an  example  of  a  remedy  that  has  been  used
historically  and  in  complementary  medicine  in  wound  dres-
sings  and  is  currently  in  use  in  sterile  wound  treatment  pro-
ducts licenced in many countries [10, 11]. Most interest centres
on  Manuka  honey,  which  is  made  from  Leptospermum
scoparium (Manuka) trees found in New Zealand and Australia
[11,  12].  Antibacterial  activity  of  many  kinds  of  honey  is
related  to  levels  of  hydrogen  peroxide;  however,  Lepto-
spermum  honey are  relatively  low in  hydrogen peroxide  and
their  antimicrobial  activity  correlates  with  levels  of  methyl
glyoxal  (MGO)  which  is  produced  by  dehydration  of
dihydroxyacetone  (DHA)  from  the  nectar  of  the  Manuka
flowers  [11  -  14].  While  hydrogen  peroxide  or  MGO  are
important  elements  of  honey’s  antibacterial  activity,  other
mediators may also play a part, including defensins, glycosides
and phenolic antioxidant compounds [11].
Sterile  Manuka  honey-based  products  such  as  Medi-
honey™  have  been  associated  with  infection  clearance  and
wound  healing  in  a  number  of  case  studies  and  series,  for
example in treatment of leg ulcers, as well as chronic Pressure
Ulcers (PUs) in Spinal Cord-Injured (SCI) patients, wound care
in  pediatric  oncology  patients  and  prevention  of  pin  site
infections during open reduction with external fixation (OREF)
for  correction  of  Charcot   deformity  in   diabetic   patients
[15 - 18]. Medical grade Manuka honey preparations have been
shown to  be  effective  in  vitro  against  both  biofilm and free-
swimming  bacteria,  including  MRSA  and  Pseudomonas
aeruginosa [9, 19]. Synergism in vitro with rifampicin has also
been  observed  against  MRSA  biofilms  and  free-swimming
bacteria  [20,  21].  The beneficial  effects  of  Manuka honey in
treating  infection  are  mediated  by  various  proposed
mechanisms, including changes in gene and protein expression
levels  of  mediators  of  bacterial  ribosomal  function,  protein
synthesis,  stress  responses,  growth  and  metabolism [10,  22],
down-regulation  of  expression  of  genes  associated  with
virulence, cell division and the tricarboxylic acid cycle [23, 24]
and reduction in expression of universal stress protein A [25].
Some studies  have suggested that  other  locally produced
kinds  of  honey  from  various  regions  including  Pakistan  and
Chile are also effective antibacterial agents in in vitro studies
[26,  27].  In  this  study,  we  compared  the  efficacy  of  local
Germania  honey  from  Saudi  Arabia  versus  Manuka  honey
MGO  550  in  the  inhibition  of  growth  of  50  MRSA  patient
samples.
2. MATERIALS AND METHODS
2.1. Bacterial Strains
50 wound culture isolates of MRSA from 50 patients were
tested for  sensitivity  to  either  Manuka honey MGO 550 or  a
local Germania commercial honey product from Saudi Arabia.
Clinical  isolates  were  identified  as  MRSA  using  routine
screening by Polymerase Chain Reaction (PCR) with the Xpert
MRSA-SA Nasal Complete G3 kit. Overnight cultures of each
strain  were  prepared  in  Muller  Hinton  broth.  Antibiotic
susceptibility profiles were determined according to the CLSI
M100 2018 criteria [28]. Samples were primarily tested using
an automated microbiology identification system (VITEK® 2;
bioMerieux, Marcy-l’Etoile, France) system for sensitivity to
the  following  antibiotics:  penicillin,  oxacillin,  gentamicin,
ciprofloxacin,  levofloxacin,  moxifloxacin,  clindamycin,  eryt-
hromycin,  quinupristin,  linezolid,  vancomycin,  tetracycline,
tigecycline,  nitrofurantoin,  rifampicin  and  trimethoprim/
sulfamethoxazole  and  for  Inducible  Clindamycin  Resistance
(ICR).  VITEK-2  tests  for  sensitivity  were  performed  by
calculating the Minimum Inhibitory Concentration (MIC) for
each antibiotic, and the interpretation of each MIC value was
assessed based on the CLSI guidelines [28]. ATCC33591 strain
was used as the control. Cefoxitin was also used to determine
the presence or absence of MRSA.
2.2. Honey Samples
Manuka Honey stock solution was made by mixing 108 g
of Manuka honey MGO 550 (1 g contains 550 μg MGO) with
100 ml Muller Hinton broth to give a final MGO concentration
of 600 μg/ml. 100 mg catalase was added to the stock solution
to neutralize hydrogen peroxide. A series of two-fold dilutions
of  the  stock  solution  were  carried  out  in  honey-free  Muller
Hinton  broth  to  give  final  concentrations  of  600  μg/ml
(undiluted),  300  μg/ml  (50%  v/v),  150  μg/ml  (25%  v/v),  75
μg/ml (12.5% v/v) and 37.5 μg/ml (6.25% v/v) (1 ml per tube).
A  0.5  McFarland  suspension  from  each  of  the  50  overnight
MRSA cultures was prepared and diluted to a cell density of 5
x 107 CFU/mL in 0.45 saline, and 5 x 105 CFU (10 μl) of each
diluted  bacterial  suspension  was  transferred  to  each  of  the
Manuka  honey  MGO  550-containing  tubes  to  give  a  final
bacterial concentration 5 x 105 CFU/ml, as per CLSI guideline
recommendations. A commercial local Germania honey stock
solution was prepared, diluted, and inoculated in the same way
as  for  Manuka  honey  for  comparison  purposes.  Bacterial
growth  was  assessed  by  checking  for  turbidity  in  Muller
Hinton  broth  after  24  h  of  culture.  We  used  DensiCHEK™
Plus  (bioMérieux)  with  the  VITEK®  2  system  to  adjust  the
turbidity  to  zero after  the samples  were inoculated.  24 hours
later,  all  samples  that  showed no  growth  by  naked  eye  were
confirmed using the DensiCHEK™ Plus device. For all tubes
that  were  scored  as  clear,  samples  were  sub-cultured  on  to
blood agar plates which were incubated for a further 24 h to
finally confirm no bacterial growth.
2.3. Data Analysis
To compare the distribution of growth versus non-growth
results between Manuka honey MGO 550 and Germania honey
at corresponding dilutions, Chi-squared analysis was used, with
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p≤0.05  accepted  as  significant.  Statistical  analysis  was
performed  using  Social  Sciences  Statistics  and  GraphPad
QuickCalcs  online  software.
3. RESULTS
The  number  of  isolates  for  which  growth  or  no  growth
occurred was scored for each dilution of Manuka honey MGO
550  and  Germania  honey  (Table  1),  (Fig.  1).  Undiluted
Manuka  honey  (600  μg/ml)  was  significantly  more  effective
than undiluted locally sourced Germania honey against MRSA
(p=0.025) Table 1; Fig. (1). At 50% v/v and 25% v/v dilutions,
Manuka  honey  was  also  significantly  more  effective  in
bacterial  killing  (p=  0.000265  and  0.000112  respectively)
Table  1;  Fig.  (1).  At  12.5%  v/v  and  6.25%  v/v,  both  honey
types were equally ineffective (Fig. 1); (Table 1), thus Manuka
honey  MGO  550  at  concentrations  of  75  μg/ml  MGO  was
ineffective in MRSA killing in vitro.
Antibiotic resistance profiles for the 50 MRSA isolates are
shown  in  Table  2.  All  strains  were  resistant  to  cefoxitin.  26
isolates had the same profile as the control ATCC33591 strain;
the remaining 24 isolates were divided between seven further
profiles. The number of isolates which grew in the presence of
undiluted, 50% v/v, 25% v/v and 12.5% v/v dilutions for both
Manuka and Germania honey was considered with respect to
antibiotic  resistance  profile  (Table  3).  Consistent  with  the
overall results, the growth of the dominant MRSA strain was
significantly less on undiluted, 50% v/v and 25% v/v Manuka
honey compared to Germania honey (Table 2). The small total
number of isolates for each of the other antibiotic susceptibility
profiles  complicated  analysis  of  any  differences  in  effect
between  the  two  honey  types  (Tables  2  and  3).
Table 1. Chi square comparison of Manuka versus Germania honey on MRSA growth.
- Bacterial Growth - -
- Yes No ATCC 33591 Chi square statistic -P value
Manuka 600 μg/ml (undiluted) 2 48 No growth 5.005 0.025
Germania undiluted stock 9 41 No growth
Manuka 300 μg/ml (50% v/v) 5 45 No growth 13.306 0.000265
Germania (1/2 diluted) (50% v/v) 21 29 Growth
Manuka 150 μg/ml (25% v/v) 11 39 No growth 14.923 0.000112
Germania 1/4 diluted
(25% v/v)
30 20 Growth
Manuka 75 μg/ml (12.5% v/v) 43 7 Growth 3.052 0.081
Germania 1/8 diluted
(12.5% v/v)
48 2 Growth
Manuka 37.5 μg/ml (6.25% v/v) 47 3 Growth 1.042 0.307
Germania 1/16 diluted (6.25% v/v) 49 1 Growth
Fig. (1). Comparison of effects of Manuka versus Germania honey on MRSA growth.
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Table 2. MRSA strain antibiotic susceptibility profiles.
- Number of strains Total
26 4 5 3 5 1 4 2 50
Antibiotic
Penicillin R R R R R R R R -
Oxacillin R R R R R R R R -
Gentamicin S S S S S S R R -
Ciprofloxacin S S S S R S R R -
Levofloxacin S S S S R S R R -
Moxifloxacin S S S S S S S R -
Clindamycin S R S R S S S R -
Erythromycin S R S R S S S R -
Quinupristin S S S S S S S S -
Linezolid S S S S S S S S -
Vancomycin S S S S S S S S -
Tetracycline S S R R R S S S -
Tigecycline S S S S S S S S -
Nitrofurantoin S S S S S S S S -
Rifampicin S S S S S S S S -
Trimethoprim/ sulfamethoxazole S S S S S R S S -
ICR NEG POS NEG NEG NEG NEG NEG POS -
ATCC33591 control strain profile
R: resistant; S: sensitive; ICR: inducible clindamycin resistance; POS: positive; NEG: negative
Table 3. Isolate growth numbers for different antibiotic susceptibility profiles.
- Number of isolates with growth Total
Man undiluted
Ger undiluted
2
7
0
2
0 0 0 0 0 0 2
9
Man 50% v/v
Ger 50% v/v
4
18
1
2
0
1
0 0 0 0 0 5
21
Man 50% v/v
Ger 50% v/v
8
25
2
2
0
1
0 1
2
0 0 0 11
30
Man 50% v/v
Ger 50% v/v
25
26
4
4
2
5
2
2
3
4
1
1
4
4
2
2
43
48
Antibiotic
Penicillin R R R R R R R R -
Oxacillin R R R R R R R R -
Gentamicin S S S S S S R R -
Ciprofloxacin S S S S R S R R -
Levofloxacin, S S S S R S R R -
Moxifloxacin S S S S S S S R -
Clindamycin S R S R S S S R -
Erythromycin S R S R S S S R -
Quinupristin S S S S S S S S -
Linezolid S S S S S S S S -
Vancomycin S S S S S S S S -
Tetracycline S S R R R S S S -
Tigecycline S S S S S S S S -
Nitrofurantoin S S S S S S S S -
Rifampicin S S S S S S S S -
Trimethoprim/ sulfamethoxazole S S S S S R S S -
ICR NEG POS NEG NEG NEG NEG NEG POS -
Man: Manuka; Ger: Germania; R: resistant; S: sensitive; ICR: inducible clindamycin resistance; POS: positive; NEG: negative
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4. DISCUSSION
In this study, we compared the in vitro  performance of a
locally sourced Germania honey against Manuka honey MGO
550  in  killing  MRSA  from  patient  wound  infections.
Consistent with previous findings, Manuka honey was effective
in preventing the growth of MRSA down to a dilution of 25%
v/v [9,  19,  27].  However,  unlike some other  kinds of  honey,
including black seed honey from Pakistan or Ulmo 90 honey
from Chile, diluted Germania honey was relatively ineffective
against  MRSA  and  it  was  significantly  less  effective  than
Manuka honey even when undiluted [26, 27]. One recent study
comparing locally produced black seed honeys from Pakistan
to Manuka honey showed that while Manuka honey was more
effective,  with  a  lower  Minimum  Inhibitory  Concentration
(MIC),  than  the  other  honeys  against  25  wound  cultures  of
MRSA and standard strains of S. aureus, P. aeruginosa and E.
coli,  the  differences  were  minimal  [26].  Importantly,  the
locally produced honeys may represent a more accessible and
affordable solution [26]. Results of another study on Chilean
honey made from the Ulmo tree (Ulmo 90 honey) showed that
in agar diffusion and MIC spectrophotometric studies the Ulmo
90  honey  was  more  effective  than  UMF®  25+  honey  against
five MRSA isolates  and equivalent  for  P. aeruginosa  and E.
coli  strains [27]. By contrast, our locally produced Germania
honey does not appear to be a good potential local alternative
to use of Manuka honey in the treatment of MRSA in wound
infections. Our data showed that Manuka honey was effective
in the suppression of growth of MRSA strains that are resistant
to  either  one  or  more  than  one  class  of  antibiotics.  Manuka
honey was significantly more effective against strains with the
dominant  MRSA  antibiotic  resistance  profile  (penicillin  and
oxacillin resistant). However, there were insufficient numbers
of isolates for each of the other seven antibiotic susceptibility
profiles  to  definitively  conclude  if  Manuka  honey  was  also
more effective for these strains.
Evidence from some studies supports the use of medical-
grade  honey-based  dressings.  A  prospective  observational
study was carried out on treatment with Medihoney™ of 121
wounds of various aetiologies during a two-year period in ten
hospitals  in  Germany  and  Austria  [29].  Wound  size  and
perceived  pain  decreased  significantly  in  response  to
Medihoney™, wound healing  was  often  rapid  and  there  was
less wound slough and/or necrosis [29]. Furthermore, in a pilot
study on pin site infections in 21 diabetic patients undergoing
Open Reduction with External Fixation (OREF) for correction
of  Charcot  deformity,  use  of  active  Leptospermum  honey-
impregnated  dressings  significantly  reduced  the  rate  of
infections  [18].  However,  other  studies  suggest  caution  is
needed in the choice of honey-based dressings. For example,
results of the randomized controlled HONEYPOT trial do not
support  the  use  of  topical  medical  grade  honey  over  topical
mupirocin for prevention of exit site infection and peritonitis in
adults on Peritoneal Dialysis (PD), although the possibility of
benefit  in  pediatric  patients  would  warrant  further  specific
trials  [30].
In Saudi Arabia, where this study was performed, MRSA
represents a significant burden both within healthcare facilities
and  in  the  community,  for  example  in  SSTIs  [1,  31  -  33].
Potentially, the use of medical grade Manuka honey could form
a  valuable  adjunctive  treatment  along  with  antibiotics,
consistent  with  experience  in  other  countries.  Bacterial
biofilms are a particular problem in chronic wound infections,
and  the  efficacy  of  Medihoney™  against  biofilms  has  been
shown in vitro [9, 19]. A recent study using MacSynergy II to
study responsiveness of S. aureus biofilms to combinations of
Medihoney™ and different antibiotics showed strong synergy
between Medihoney™ and rifampicin in reduction of biofilm
biomass  and  embedded  cell  viability  [21].  The  extent  of  the
reduction would be likely to have in vivo significance [21]. The
study  also  showed,  however,  that  Medihoney™ at  subinhib-
itory concentrations had antagonistic effects on clindamycin,
gentamicin, and oxacillin treatment, indicating the importance
of  establishing  effective  concentrations  and  combinations.
Synergism  between  rifampicin  and  Medihoney™  against
MRSA and clinical isolates of S. aureus has also been shown in
checkerboard microdilution assays, time-kill curve experiments
and agar diffusion assays, along with a reduction in emergence
of rifampicin-resistant S. aureus in vitro, suggesting that use of
Medihoney™ as an adjunctive treatment could have benefits in
reducing  the  risk  of  antibiotic  resistance  [20].  Other  in  vitro
studies have shown that co-treatment with Manuka honey and
oxacillin  could  synergistically  inhibit  MRSA  in  vitro  and
restore oxacillin sensitivity [34]. Cultivation of bacterial strains
including MRSA, P. aeruginosa, E. coli and S. epidermis in the
presence  of  sub-lethal  concentrations  of  Manuka  honey  and
under conditions in which antibiotic-resistance would rapidly
develop  did  not  lead  to  the  emergence  of  honey-resistant
bacterial  strains  [10,  35].  These  results  suggest  an  important
further  advantage  to  use  of  medical-grade  honey products  in
the context of the rise of antibiotic resistance [10, 35].
CONCLUSION
In  conclusion,  locally  sourced  Germania  honey  is  less
effective  in  vitro  than  Manuka  honey  MGO  550  in  killing
MRSA from patient wound infections. Further studies could be
carried out to determine if Germania honey is more effective
against other bacterial species. Use of Manuka honey dressings
should  be  considered  in  MRSA  wound  dressing  in  Saudi
Arabia.
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